Related Experiment Video

Updated: Mar 1, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

18.5K

Prioritizing the most needed formulations to accelerate paediatric antiretroviral therapy scale-up

Martina Penazzato1, Claudia Palladino, Nandita Sugandhi

  • 1aHIV Department, World Health Organization, Geneva, SwitzerlandbResearch Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, University of Lisbon, Lisbon, PortugalcClinton Health Access Initiative, New York, USA.

Current Opinion in HIV and AIDS
|June 2, 2017
PubMed

Insights

Optimizing antiretroviral therapy (ART) for children with HIV requires better drug options and strategies. Current efforts focus on dolutegravir-based regimens and protease inhibitors for improved pediatric HIV treatment outcomes.

Area of Science:

  • Pediatric infectious diseases
  • Antiretroviral therapy research
  • HIV/AIDS treatment optimization

Background:

  • Global initiatives aim for rapid 2018 targets in pediatric HIV treatment.
  • Success hinges on improved pediatric antiretrovirals and treatment strategies.
  • Limited treatment options necessitate optimization of pediatric ART.

Purpose of the Study:

  • Review features, challenges, and developments in pediatric HIV treatment.
  • Determine optimal regimen sequencing and drug utilization for children.
  • Outline a vision for medium and long-term treatment optimization in pediatric HIV.

Main Methods:

  • Literature review of recent developments in pediatric antiretroviral therapy.
  • Analysis of current treatment guidelines and drug availability for children.
  • Expert group recommendations on regimen sequencing and drug use.

Main Results:

  • Dolutegravir-based regimens are the long-term goal for first-line pediatric ART.
  • Protease inhibitor-based regimens remain crucial for second and third-line treatment.
  • Urgent need for optimized pediatric HIV treatment, improved drug access, and new formulations.

Conclusions:

  • Recent advancements in pediatric ART allow for reconsideration of treatment optimization strategies.
  • Further evidence is required to ensure optimal treatment options from infancy through adulthood.
  • Continued research and development are essential for advancing pediatric HIV care.
Abstract

More Related Videos

Methods Development for Blood Borne Macrophage Carriage of Nanoformulated Antiretroviral Drugs18:46

Methods Development for Blood Borne Macrophage Carriage of Nanoformulated Antiretroviral Drugs

Published on: December 9, 2010

13.7K
An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

19.4K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
341
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
445
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
392
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
387
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
293
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
3.2K